Response to cytotoxic chemotherapy and overall survival in non-small cell lung cancer patients with positive or negative ERCC1 expression

J Bras Pneumol. 2018 May-Jun;44(3):245-246. doi: 10.1590/S1806-37562017000000236.

[Article in English, Portuguese]

Authors

Helen Naemi Honma¹, Maurício Wesley Perroud Jr¹, André Moreno Morcillo², José Vassallo³, Lair Zambon¹

Affiliations

¹ . Departamento de Clínica Médica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas (SP) Brasil.
² . Departamento de Pediatria, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas (SP) Brasil.
³ . Departamento de Anatomopatologia, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas (SP) Brasil.

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Agents / therapeutic use
Carcinoma, Non-Small-Cell Lung* / chemistry
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / mortality
Cisplatin / therapeutic use
DNA-Binding Proteins / analysis*
Endonucleases / analysis*
Female
Humans
Immunohistochemistry
Lung Neoplasms* / chemistry
Lung Neoplasms* / drug therapy
Lung Neoplasms* / mortality
Male
Middle Aged
Paclitaxel / therapeutic use
Time Factors
Treatment Outcome

Substances

Antineoplastic Agents
DNA-Binding Proteins
ERCC1 protein, human
Endonucleases
Paclitaxel
Cisplatin